2019 American Transplant Congress
Hepatitis C Positive Donor to Negative Recipient Kidney Transplantation: A Single Center Real World Experience
North Shore University Hospital, Manhasset, NY
*Purpose: Several small studies have shown that transplanting a hepatitis C virus (HCV) negative recipient with a HCV positive donor is feasible in a research…2019 American Transplant Congress
Real World Impact of HCV Viremic Solid Organs on Waitlist Times
*Purpose: The advent of direct acting antiviral agents (DAAs) has led to a paradigm shift in the approach to hepatitis C (HCV) infected organs. The…2019 American Transplant Congress
Rapid Growth of HCV-Infected Donors for HCV-Uninfected Kidney and Liver Transplant Recipients in the United States
Johns Hopkins University, Baltimore, MD
*Purpose: Several single-center reports of using HCV-viremic organs for HCV-uninfected recipients were recently published in the US. In light of recent DAA introduction, we sought…2019 American Transplant Congress
Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor
1University of Pennsylvania, Philadelphia, PA, 2Abbott Labs, Chicago, IL
*Purpose: The opioid epidemic has increased the number of deceased donors with active (Ab+/NAT+) or prior (Ab+/NAT-) HCV infection. Increased utilization of these donor organs…2019 American Transplant Congress
Renal Outcomes from Expander-1: Pilot Study of HCV+ Donor Kidneys for HCV- Kidney Recipients
*Purpose: Direct acting antivirals (DAAs) have led to high cure rates (>95%) for hepatitis C. Utilization of HCV+ donor kidneys for patients with advanced kidney…2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…2019 American Transplant Congress
Results from the LIVE-C Free Trial
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…2019 American Transplant Congress
Impact of Donor Hepatitis C Virus Infection on Kidney Transplant Outcomes in the Direct Acting Antiretroviral Era: Time to Revise the KDPI?
University of Louisville, Louisville, KY
*Purpose: The kidney donor risk index (KDRI), upon which the kidney donor profile index (KDPI) used for renal allocation is based, was derived before the…2019 American Transplant Congress
Ultra-Short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Two recent pilot trials have shown that transplanting hepatitis C (HCV) viremic kidneys in to HCV negative recipients is feasible. These trials used 12…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 28
- Next Page »